The Structure and Biological Features of Fibrinogen and Fibrin

Abstract: Fibrinogen and fibrin play important, overlapping roles in blood clotting, fibrinolysis, cellular and matrix interactions, inflammation, wound healing, and neoplasia. These events are regulated to a large extent by fibrin formation itself and by complementary interactions between specific binding sites on fibrin(ogen) and extrinsic molecules including proenzymes, clotting factors, enzyme inhibitors, and cell receptors. Fibrinogen is comprised of two sets of three polypeptide chains termed Aα, Bβ, and γ, that are joined by disulfide bridging within the N‐terminal E domain. The molecules are elongated 45‐nm structures consisting of two outer D domains, each connected to a central E domain by a coiled‐coil segment. These domains contain constitutive binding sites that participate in fibrinogen conversion to fibrin, fibrin assembly, crosslinking, and platelet interactions (e.g., thrombin substrate, Da, Db, γXL, D:D, αC, γA chain platelet receptor) as well as sites that are available after fibrinopeptide cleavage (e.g., E domain low affinity non‐substrate thrombin binding site); or that become exposed as a consequence of the polymerization process (e.g., tPA‐dependent plasminogen activation). A constitutive plasma factor XIII binding site and a high affinity non‐substrate thrombin binding site are located on variant γ′ chains that comprise a minor proportion of the γ chain population. Initiation of fibrin assembly by thrombin‐mediated cleavage of fibrinopeptide A from Aα chains exposes two EA polymerization sites, and subsequent fibrinopeptide B cleavage exposes two EB polymerization sites that can also interact with platelets, fibroblasts, and endothelial cells. Fibrin generation leads to end‐to‐middle intermolecular Da to EA associations, resulting in linear double‐stranded fibrils and equilaterally branched trimolecular fibril junctions. Side‐to‐side fibril convergence results in bilateral network branches and multistranded thick fiber cables. Concomitantly, factor XIII or thrombin‐activated factor XIIIa introduce intermolecular covalent ε‐(γ glutamyl)lysine bonds into these polymers, first creating γ dimers between properly aligned C‐terminal γXL sites, which are positioned transversely between the two strands of each fibrin fibril. Later, crosslinks form mainly between complementary sites on γ chains (forming γ‐polymers), and even more slowly among γ dimers to create higher order crosslinked γ trimers and tetramers, to complete the mature network structure.

[1]  K. Kaplan,et al.  The binding of thrombin by fibrin. , 1979, The Journal of biological chemistry.

[2]  J. Hainfeld,et al.  Identification and mass analysis of human fibrinogen molecules and their domains by scanning transmission electron microscopy. , 1981, Journal of molecular biology.

[3]  W. Brandt,et al.  Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff adder venom (Bitis arietans) acting at cross-linked sites of the gamma-chain. Sequence of carboxy-terminal cyanogen bromide gamma-chain fragments. , 1987, Biochemistry.

[4]  T. Tamaki,et al.  Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor , 1981 .

[5]  J. Gris,et al.  Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism. , 1993, The Journal of laboratory and clinical medicine.

[6]  D. Cheresh,et al.  Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. , 1992, The Journal of biological chemistry.

[7]  G. Smejkal,et al.  Isolation and Characterization of the Fibrin Intermediate Arising from Cleavage of One Fibrinopeptide A from Fibrinogen* , 1996, The Journal of Biological Chemistry.

[8]  D. Collen On the Regulation and Control of Fibrinolysis , 1980, Thrombosis and Haemostasis.

[9]  D. B. Smith,et al.  Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots. , 1987, The Journal of laboratory and clinical medicine.

[10]  J. Finlayson,et al.  Human fibrinogen heterogeneities. 3. Identification of chain variants. , 1972, The Journal of biological chemistry.

[11]  R. Hill,et al.  Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Siebenlist,et al.  Protransglutaminase (Factor XIII) Mediated Crosslinking of Fibrinogen and Fibrin* , 2001, Thrombosis and Haemostasis.

[13]  D. Mosher Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. , 1975, The Journal of biological chemistry.

[14]  S. Kimura,et al.  Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. , 1986, The Journal of biological chemistry.

[15]  W. Nieuwenhuizen,et al.  Evaluation of the factors contributing to fibrin-dependent plasminogen activation. , 1998, Thrombosis and haemostasis.

[16]  S. Thorsen,et al.  Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. , 1984, European journal of biochemistry.

[17]  L. Lorand,et al.  The complementary aggregation sites of fibrin investigated through examination of polymers of fibrinogen with fragment E. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Vilaire,et al.  Exposure of platelet fibrinogen receptors by ADP and epinephrine. , 1979, The Journal of clinical investigation.

[19]  J. Hainfeld,et al.  The location of the carboxy-terminal region of chains in fibrinogen and fibrin D domains , 1998 .

[20]  C. Francis,et al.  Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. , 1993, Blood.

[21]  C. Francis,et al.  Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. , 1989, The Journal of clinical investigation.

[22]  J. Hainfeld,et al.  Orientation of the Carboxy-terminal Regions of Fibrin γ Chain Dimers Determined from the Crosslinked Products Formed in Mixtures of Fibrin, Fragment D, and Factor XIIIa , 1995, Thrombosis and Haemostasis.

[23]  M. Mosesson,et al.  Cross-linking of Plasminogen Activator Inhibitor 2 and α2-Antiplasmin to Fibrin(ogen)* , 2000, The Journal of Biological Chemistry.

[24]  M. Rånby,et al.  Studies on the kinetics of plasminogen activation by tissue plasminogen activator. , 1982, Biochimica et biophysica acta.

[25]  R. Williams,et al.  MORPHOLOGY OF FIBRINOGEN MONOMERS AND OF FIBRIN PROTOFIBRILS * , 1983, Annals of the New York Academy of Sciences.

[26]  W. Nieuwenhuizen,et al.  The sequence gamma-(312-324) is a fibrin-specific epitope. , 1991, Blood.

[27]  K. Siebenlist,et al.  Factors affecting γ-chain multimer formation in cross-linked fibrin , 1992 .

[28]  G. Müller‐Berghaus,et al.  Crosslinking of fibrinogen to immobilized DesAA-fibrin. , 1985, Thrombosis research.

[29]  Tami L. Bach,et al.  Endothelial Cell VE-cadherin Functions as a Receptor for the β15–42 Sequence of Fibrin* , 1998, The Journal of Biological Chemistry.

[30]  J. Hainfeld,et al.  The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys). , 1995, The Journal of clinical investigation.

[31]  S. Timmons,et al.  Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. , 1984, Biochemistry.

[32]  T. Odrljin,et al.  Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. , 1996, Blood.

[33]  C. Southan,et al.  COVALENT STRUCTURE OF FIBRINOGEN , 1983, Annals of the New York Academy of Sciences.

[34]  R. Exley,et al.  Monocyte Plasminogen Activator Inhibitor 2 (PAI-2) Inhibits u-PA-mediated Fibrin Clot Lysis and Is Cross-linked to Fibrin , 1999, Thrombosis and Haemostasis.

[35]  M. Mosesson,et al.  Interactions Among Heparin, Cold-Insoluble Globulin, and Fibrinogen in Formation of the Heparin Precipitable Fraction of Plasma , 1977, Thrombosis and Haemostasis.

[36]  J. Hermans,et al.  Structure of the fibrin protofibril. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Harpel,et al.  Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. , 1985, The Journal of biological chemistry.

[38]  J. Weisel,et al.  Role of the alpha C domains of fibrin in clot formation. , 1994, Biochemistry.

[39]  E. Davie,et al.  gamma and gamma' chains of human fibrinogen are produced by alternative mRNA processing. , 1984, Biochemistry.

[40]  B. Blombäck,et al.  A two-step fibrinogen–fibrin transition in blood coagulation , 1978, Nature.

[41]  C. Soria,et al.  Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. , 2001, Thrombosis research.

[42]  S. Timmons,et al.  Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. , 1983, Thrombosis research.

[43]  S. Lord,et al.  Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr. , 1992, The Journal of clinical investigation.

[44]  R. Doolittle,et al.  Hybrid fibrin: proof of the intermolecular nature of - crosslinking units. , 1971, Biochemical and biophysical research communications.

[45]  J. A. Méndez,et al.  Twofold symmetry of human fibrinogen proved at the beta chain distal domains by monoclonal-immunoelectron microscopy and image analysis. , 1996, Biochemistry.

[46]  C. Cierniewski,et al.  Conservation of human fibrinogen conformation after cleavage of the B beta chain NH2 terminus. , 1985, The Journal of biological chemistry.

[47]  S. Santoro,et al.  Competition for related but nonidentical binding sites on the glycoprotein IIb-IIIa complex by peptides derived from platelet adhesive proteins , 1987, Cell.

[48]  J. Wall,et al.  Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular junction. , 1993, Blood.

[49]  W. Mangel,et al.  Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin. , 1985, Biochemistry.

[50]  K. Siebenlist,et al.  Identification and Characterization of the Thrombin Binding Sites on Fibrin* , 1996, The Journal of Biological Chemistry.

[51]  R. Clark,et al.  Human Fibroblasts Bind Directly to Fibrinogen at RGD Sites through Integrin αvβ3 , 1997 .

[52]  A. Sahni,et al.  Fibrinogen and Fibrin Protect Fibroblast Growth Factor-2 from Proteolytic Degradation , 2000, Thrombosis and Haemostasis.

[53]  E. Davie,et al.  Crystal structure of a 30 kDa C-terminal fragment from the γ chain of human fibrinogen , 1997 .

[54]  J. Loscalzo,et al.  Lipoprotein(a), fibrin binding, and plasminogen activation. , 1990, Arteriosclerosis.

[55]  H. Scheraga,et al.  The Fibrinogen-Fibrin Conversion1 , 1957 .

[56]  T. Edgington,et al.  Human Platelets Possess an Inducible and Saturable Receptor Specific for Fibrinogen , 1979, Thrombosis and Haemostasis.

[57]  S. Lam,et al.  Evidence that arginyl-glycyl-aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets. , 1987, The Journal of biological chemistry.

[58]  Y. Matsuka,et al.  Cross-Linking of Fibronectin to C-Terminal Fragments of the Fibrinogen α-Chain by Factor XIIIa , 1997, Journal of protein chemistry.

[59]  C. Francis,et al.  Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. , 1993, The Journal of biological chemistry.

[60]  G. Tsurupa,et al.  Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains. , 2001, Biochemistry.

[61]  M. Gawinowicz,et al.  Identification of the α Chain Lysine Donor Sites Involved in Factor XIIIa Fibrin Cross-linking* , 1996, The Journal of Biological Chemistry.

[62]  H. Azuma,et al.  Congenital Histidine-Rich Glycoprotein Deficiency , 1993, Thrombosis and Haemostasis.

[63]  L. Hervio,et al.  Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. , 1995, Biochemistry.

[64]  D. Cheresh Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[65]  B. M. Siegel,et al.  An electron microscopic investigation of the polymerization of bovine fibrin monomer. , 1972, Journal of molecular biology.

[66]  B. Gordon,et al.  Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[67]  F. Rodeghiero,et al.  High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. , 1993, Thrombosis research.

[68]  L. Lorand,et al.  Contact with the N Termini in the Central E Domain Enhances the Reactivities of the Distal D Domains of Fibrin to Factor XIIIa(*) , 1995, The Journal of Biological Chemistry.

[69]  A. Chapel,et al.  Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIbIIIa. , 1989, The Journal of biological chemistry.

[70]  Jian-Zhong Zhang,et al.  Identification of B @ Chain Domains Involved in Human Fibrinogen Assembly * , 2001 .

[71]  A. Laudano,et al.  Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. , 1980, Biochemistry.

[72]  N. Hasegawa,et al.  Location of the binding site "b" for lateral polymerization of fibrin. , 1990, Thrombosis research.

[73]  K. Siebenlist,et al.  Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. , 1996, Biochemistry.

[74]  R. Willette,et al.  Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions. , 1998, Circulation research.

[75]  R. Doolittle,et al.  Dimeric half-molecules of human fibrinogen are joined through disulfide bonds in an antiparallel orientation. , 1983, Biochemistry.

[76]  L. Medved,et al.  Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. , 1996, Biochemistry.

[77]  A. Sahni,et al.  Potentiation of Endothelial Cell Proliferation by Fibrin(ogen)-bound Fibroblast Growth Factor-2* , 1999, The Journal of Biological Chemistry.

[78]  K. Siebenlist,et al.  The polymerization and thrombin-binding properties of des-(B beta 1-42)-fibrin. , 1990, The Journal of biological chemistry.

[79]  J Martinez,et al.  Fibrin II induces endothelial cell capillary tube formation , 1995, The Journal of cell biology.

[80]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[81]  S. Lord,et al.  Strategy for recombinant multichain protein synthesis: fibrinogen B beta-chain variants as thrombin substrates. , 1996, Biochemistry.

[82]  J. Hermans,et al.  Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers. , 1981, Science.

[83]  N. Kirschbaum,et al.  Characterization of the gamma chain platelet binding site on fibrinogen fragment D. , 1992, Blood.

[84]  K. Siebenlist,et al.  Evidence of intramolecular cross-linked A alpha.gamma chain heterodimers in plasma fibrinogen. , 1996, Biochemistry.

[85]  S. Brennan,et al.  The Amino Acid Sequence in Fibrin Responsible for High Affinity Thrombin Binding , 2001, Thrombosis and Haemostasis.

[86]  H. Kanaide,et al.  Cross-linking of fibrinogen and fibrin by fibrin-stablizing factor (factor XIIIa). , 1976, The Journal of laboratory and clinical medicine.

[87]  Hans,et al.  The Sequence y-( 312-324 ) Is a Fibrin-Specific Epitope , 2003 .

[88]  S. Madoiwa,et al.  Fibroblasts Spread on Immobilized Fibrin Monomer by Mobilizing a β1-class Integrin, Together with a Vitronectin Receptor αvβ3 on Their Surface* , 1997, The Journal of Biological Chemistry.

[89]  S. Sherry,et al.  The preparation and properties of human fibrinogen of relatively high solubility. , 1966, Biochemistry.

[90]  L. Leung Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. , 1986, The Journal of clinical investigation.

[91]  K. Carlsson,et al.  Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. , 1994, Thrombosis research.

[92]  J. F. Johnson,et al.  An Antithrombin Reaction Related to Prothrombin Activation , 1953 .

[93]  D. Powell,et al.  Insulin-like Growth Factor-binding Protein-3 Binds Fibrinogen and Fibrin* , 1999, The Journal of Biological Chemistry.

[94]  N. Kirschbaum,et al.  Characterization of the y Chain Platelet Binding Site on Fibrinogen Fragment , 2022 .

[95]  J. Soria,et al.  Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin). , 1987, Blood.

[96]  Y. Sakata,et al.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. , 1982, The Journal of clinical investigation.

[97]  D. Altieri,et al.  The structural motif glycine 190-valine 202 of the fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2, Mac-1) and promotes leukocyte adhesion. , 1993, The Journal of biological chemistry.

[98]  J. Fontcuberta,et al.  A New Case of Hereditary Histidine-rich Glycoprotein Deficiency with Familial Thrombophilia , 1996, Thrombosis and Haemostasis.

[99]  D. Handley,et al.  Fibrinogen New York 1: The structural, functional, and genetic defects and an hypothesis of the role of fibrin in the regulation of coagulation and fibrinolysis , 1986 .

[100]  R. Doolittle,et al.  Crystal structure of fragment double-D from human fibrin with two different bound ligands. , 1998, Biochemistry.

[101]  J. Hainfeld,et al.  The covalent structure of factor XIIIa crosslinked fibrinogen fibrils. , 1995, Journal of structural biology.

[102]  J. Weisel,et al.  Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated alpha C fragments on polymerization. , 1993, The Journal of biological chemistry.

[103]  A. Sahni,et al.  Binding of Basic Fibroblast Growth Factor to Fibrinogen and Fibrin* , 1998, The Journal of Biological Chemistry.

[104]  R. Doolittle,et al.  Photoaffinity labeling of the primary fibrin polymerization site: isolation and characterization of a labeled cyanogen bromide fragment corresponding to gamma-chain residues 337-379. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Y. Inada,et al.  Distinctive role of histidine-16 of the B beta chain of fibrinogen in the end-to-end association of fibrin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[106]  W. Bode,et al.  A player of many parts: the spotlight falls on thrombin's structure. , 1993, Thrombosis research.

[107]  J. Finlayson,et al.  Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations. , 1963, The Journal of clinical investigation.

[108]  M. Mosesson,et al.  Carboxy-terminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma'). , 1981, Biochemistry.

[109]  J. Shainoff,et al.  Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase. Identification of a rapid mode of hybrid alpha-/gamma-chain cross-linking that is promoted by the gamma-chain cross-linking. , 1991, The Journal of biological chemistry.

[110]  A. Shimizu [Fibrinogen-fibrin conversion]. , 1990, Seikagaku. The Journal of Japanese Biochemical Society.

[111]  E. Davie,et al.  The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[112]  M. Mosesson FIBRINOGEN HETEROGENEITY * , 1983, Annals of the New York Academy of Sciences.

[113]  E. Hewat,et al.  Electron microscope structural study of modified fibrin and a related modified fibrinogen aggregate. , 1983, Journal of molecular biology.

[114]  E. Davie,et al.  The role of amino-terminal disulfide bonds in the structure and assembly of human fibrinogen. , 1993, Biochemical and biophysical research communications.

[115]  J. Shainoff,et al.  FIBRINOPEPTIDE B IN FIBRIN ASSEMBLY AND METABOLISM: PHYSIOLOGIC SIGNIFICANCE IN DELAYED RELEASE OF THE PEPTIDE * , 1983, Annals of the New York Academy of Sciences.

[116]  J. Mcdonagh,et al.  Amino acid sequence of the factor XIIIa acceptor site in bovine plasma fibronectin , 1981, FEBS letters.

[117]  W. Nieuwenhuizen,et al.  The sequence Aα-(154 – 159) of fibrinogen is capable of accelerating the t‐PA catalysed activation of plasminogen , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[118]  T. Ugarova,et al.  Localization of a fibrin polymerization site complementary to Gly‐His‐Arg sequence , 1993, FEBS letters.

[119]  K. Siebenlist,et al.  Factors affecting gamma-chain multimer formation in cross-linked fibrin. , 1992, Biochemistry.

[120]  R. Doolittle,et al.  - cross-linking sites in human and bovine fibrin. , 1971, Biochemistry.

[121]  A. Laudano,et al.  Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[122]  B. Blombäck,et al.  Disulfide bridges in nh2 -terminal part of human fibrinogen. , 1976, Thrombosis research.

[123]  N. Ohkura,et al.  A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. , 1997, Blood.

[124]  H. Scheraga,et al.  Localization of the binding site on fibrin for the secondary binding site of thrombin. , 1988, Biochemistry.

[125]  J. Koehn,et al.  Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene. , 1985, The Journal of biological chemistry.

[126]  R. Albrecht,et al.  Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[127]  E. Plow,et al.  Fibrinogen Is a Ligand for Integrin α5β1 on Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[128]  W. Seegers,et al.  NOTE ON THE ADSORPTION OF THROMBIN ON FIBRIN. , 1945, Science.

[129]  C. Francis,et al.  Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. , 1995, Blood.

[130]  J. Soria,et al.  Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta- fibrin) , 1987 .

[131]  D. Rouy,et al.  Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin. , 1992, Biochimica et biophysica acta.

[132]  C. Francis,et al.  Endothelial cell responses to fibrin mediated by FPB cleavage and the amino terminus of the beta chain. , 1993, Blood cells.

[133]  M. Mosesson,et al.  Dysfibrinogenemia and Thrombosis , 1999, Seminars in thrombosis and hemostasis.

[134]  S. Brennan,et al.  Fibrinogen Naples I (Bβ A68T) nonsubstrate thrombin-binding capacities , 2001 .

[135]  C. Francis,et al.  Heparin-binding domain of fibrin mediates its binding to endothelial cells. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[136]  J. Ferry The Mechanism of Polymerization of Fibrinogen. , 1952, Proceedings of the National Academy of Sciences of the United States of America.

[137]  W. Nieuwenhuizen,et al.  Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. , 2000, Biochemistry.

[138]  K. Siebenlist,et al.  Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[139]  E. Levin Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[140]  M. Zabinski,et al.  Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. , 1988, Biochemistry.

[141]  C. Redman,et al.  Identification of B beta chain domains involved in human fibrinogen assembly. , 1992, The Journal of biological chemistry.

[142]  E. Gabazza,et al.  Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. , 1995, European journal of biochemistry.

[143]  L. Bachmann,et al.  Chromatography and electron microscopy of cross‐linked fibrin polymers—a new model describing the cross‐linking at the DD‐trans contact of the fibrin molecules , 1988, Biopolymers.

[144]  M. Margaglione,et al.  A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen). , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.